First Author | Year | Country | Tumor stage | Regimen of chemotherapy | Genotyping method | Nunber of cases | Resistant | Responder | P (HWE) | NOS score | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CC | CT | TT | CC | CT | TT | |||||||||
Kang | 2006 | Korean | I-IV | platinum-based chemotherapy | Snapshot | 60 | 15 | 5 | 0 | 20 | 16 | 4 | 0.763 | 8 |
Smith | 2007 | USA | I-IV | platium ± paditaxel chemotherapy | PCR–RFLP | 176 | 11 | 22 | 15 | 23 | 60 | 45 | 0.701 | 8 |
Steffensen | 2008 | Danish | II-IV | carboplatin and cyclophosphamide combined-chemotherapy | TaqMan assay-based Real time PCR | 100 | 3 | 7 | 2 | 12 | 34 | 42 | 0.239 | 8 |
Steffensen | 2011 | Danish | I-IV | Combined with carboplatin and paclitaxel | PCR–RFLP | 157 | 2 | 4 | 7 | 15 | 71 | 58 | 0.321 | 8 |
Bösmüller | 2011 | Germany | I-III | Standard carboplatin-taxane | PCR–RFLP | 41 | 6 | 5 | 3 | 7 | 9 | 11 | 0.098 | 8 |
Moxley | 2013 | USA | IIIB-IV | Platium- Based Chemotherapy | PCR–RFLP | 64 | 10 | 13 | 9 | 14 | 8 | 10 | 0.005 | 8 |
Qi BL | 2013 | China | I-IV | Platinum-based combination | Snapshot | 220 | 38 | 26 | 9 | 78 | 67 | 2 | 0.003 | 7 |
Huo XY | 2017 | China | I-IV | TP (paclitaxel / docetaxel + cisplatin / carboplatin / oxaliplatin) | PCR–RFLP | 280 | 43 | 29 | 16 | 104 | 82 | 6 | 0.049 | 7 |
Yang SY | 2017 | China | III-IV | Cisplatin / carboplatin, combined with cyclophosphamide / paclitaxel | PCR–RFLP | 209 | 28 | 31 | 12 | 70 | 67 | 1 | 0.000 | 7 |
Bao Y | 2020 | China | II-IV | cisplatin based Chemotherapy | PCR–RFLP | 559 | 209 | 124 | 47 | 115 | 55 | 9 | 0.473 | 8 |